Loading...
•
Sep 30, 2021
Amphastar Q3 2021 Earnings Report
Reported record sales driven by glucagon, Primatene Mist, and epinephrine products.
Key Takeaways
Amphastar Pharmaceuticals reported a strong third quarter with net revenues of $112.2 million, a 34% increase compared to the same period last year. GAAP net income was $29.5 million, or $0.59 per share, while adjusted non-GAAP net income was $23.0 million, or $0.46 per share.
Net revenues reached $112.2 million for the third quarter.
GAAP net income was $29.5 million, or $0.59 per share, for the third quarter.
Adjusted non-GAAP net income was $23.0 million, or $0.46 per share, for the third quarter.
Growth was driven by glucagon, Primatene Mist®, and epinephrine products.
Revenue by Segment
Forward Guidance
The company expects glucagon, Primatene Mist®, and epinephrine products to continue to be the primary drivers of growth until further approvals for products in their pipeline are received, which they project will happen in 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...